Research
Accelerating Diabetes Technology
SDRI’s Clinical Research Changes Lives
Our dedicated clinical research team is making profound strides in developing and bringing new devices to market, significantly improving the lives of those living with diabetes
The Impact
At SDRI, we are at the forefront of diabetes technology innovation. We have participated in key pivotal trials of commercial automated insulin delivery devices, and served as a clinical site in the trials for Medtronic’s closed-loop technology, Tandem Diabetes Control- IQ and Basal-IQ technology, and Insulet’s Automated Insulin Delivery System Omnipod 5.
Our dedicated clinical research team is making profound strides in developing and bringing new devices to market, significantly improving the lives of those living with diabetes.
Insulin Studies
SDRI has participated in key drug development clinical trials including:
- Mannkind’s Afrezza inhaled insulin
- Eli Lilly’s once-weekly basal insulin and GLP-1 inhibitors
- Novo Nordisk’s fast acting insulin FiAsp
- Comparing Tresiba and Lantus over long haul travel
- Comparison between Sanofi’s drugs, Toujeo and Lantus
Timeline
Artificial Pancreas Technology at SDRI
The research studios conducted by Sansum Diabetes Research Institute (SDR) play a pivotal role in advancing diabetes care, particularly in the development of technologies that significantly enhance the management of type 1 diabetes. These studies accomplished several important milestones:
- SDRI led U.S. research on implanted glucose sensors and insulin pumps, and, in collaboration with UCSB, secured the first U.S. patent for an algorithm essential to automated glucose control in Artificial Pancreas systems.
- SDRI’s contributions to the global JDRF Artificial Pancreas Project were recognized as one of the top 10 advancements in diabetes research.
- SDRI pioneered the development of run-to-run algorithms to enhance automated. insulin dosing, enrolled the first patient in a study of the innovative Omnipod Automated glucose Control System, and played a key role in the pivotal trials for Tandem’s Basal-IQ and Control-IQ technologies.
- SDRI collaborated on groundbreaking studies using automated insulin delivery during pregnancy, demonstrating the safety and efficacy of a pregnancy-specific algorithm for women with type 1 diabetes
These studies collectively advanced the field of diabetes technology, contributing to the development of more sophistacted, user-friendly, and effective management tools. The outcomes of these studies have directly improved the lives of individuals with T1D by offering better glucose control, reducing the risk of complications, and enhancing overall quality of life.
Contact
Temporary Location
5425 Hollister Ave, Suite 230
Santa Barbara, CA 93111
Phone: 805-682-7638
Fax: 805-682-3332
Patient Care: 805-682-4793
Tax ID # 95-1684086
